Results 161 to 170 of about 55,691 (247)

Efficacy and Safety of Ultra‐Low Starting Dose Febuxostat Titration in Male Patients With Primary Gout

International Journal of Rheumatic Diseases, Volume 29, Issue 9, September 2026.
ABSTRACT Background Since gout is a common metabolic arthritis caused by urate crystal deposition, urate‐lowering therapy (ULT) is clearly indicated, but the initiation of ULT frequently causes paradoxical acute flares that in turn impair patient adherence.
Sun Huizhen, Li Yadi, Guo Lin, Sun Rui, Guo Xuemei, Li Ping   +5 more
wiley   +1 more source

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Overcoming Drug Loading and Dosage Volume Challenges of Adsorption-Solidified SNEDDS by pH-Modulation Strategy: Atorvastatin Calcium and Glibenclamide as Model Drugs. [PDF]

Pharmaceutics
Sherif AY, Altamimi MA.
europepmc   +1 more source

Furong Tongmai Capsule Ameliorates Atherosclerosis in ApoE−/− Mice by Modulating Gut Microbiota, Arachidonic Acid Metabolism and Macrophage Polarization

Journal of Cellular and Molecular Medicine, Volume 30, Issue 17, September 2026.
ABSTRACT Furong Tongmai capsule (FRTM) is a traditional Chinese medicine formula with reported lipid‐lowering and anti‐inflammatory activities, but its mechanisms in atherosclerosis (AS) remain unclear. In ApoE−/− mice fed a high‐fat diet, FRTM administration improved serum lipid profiles by reducing total cholesterol, triglycerides and low‐density ...
Shuquan Lv, Hanzhou Li, Yuming Wang, Xiuxiu Sang, Feng Wang, Jing Yang, Lirong Fan, Ziang Ma, Lixin Wang, Yuhong Bian, Huantian Cui   +10 more
wiley   +1 more source

Atorvastatin Mitigates Hypercholesterolemia-Induced Alterations in Cerebral Mitochondrial Dehydrogenases in Rats. [PDF]

Int J Mol Sci
Belczyk M, Gawedzka A, Drag J, Stelmach O, Knapik-Czajka M.   +4 more
europepmc   +1 more source

Autophagy in MASLD: A Metabolic and Precision Medicine Perspective

Liver International, Volume 46, Issue 9, September 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide and a major contributor to cirrhosis and hepatocellular carcinoma (HCC). While metabolic triggers such as obesity and insulin resistance are key drivers of MASLD, growing evidence has identified defects in intracellular quality
Alessandra Cazzaniga, Silvia Frigo, Alessandro Cherubini, Eniada Rrapaj, Luca Valenti   +4 more
wiley   +1 more source

[¹⁸F]FDG PET/CT as an endpoint marker in drug interventional studies in atherosclerosis - a structured review. [PDF]

EJNMMI Res
Gijsen CEW, Mottaghy FM, Tawakol A, Wildberger JE, Bucerius J.   +4 more
europepmc   +1 more source

Comparative Effects of Different Statin Regimens on Postoperative Outcomes in Isolated Coronary Artery Bypass Grafting: A Propensity Score-Matched Analysis. [PDF]

J Clin Med
Beyazal OF, Temizturk Z, Aydin C, Donbaloglu MO, Erdal A, Citak SS, Kayalar N, Yanartas M.   +7 more
europepmc   +1 more source

Sex-Dependent Vascular Responses to Atorvastatin Across Multiple Arterial Beds in a Mouse Model of Marfan Syndrome. [PDF]

Cells
Hunt P, Huynh K, Gusek B, Stimpson A, Rahimian R, Esfandiarei M.   +5 more
europepmc   +1 more source

BASTA trial: protocol for a randomised, double-blind, placebo-controlled, crossover trial investigating the effects of atorvastatin on bile acid diarrhoea. [PDF]

BMJ Open
Lynggaard MB, Olsen SS, Forman JL, Kårhus ML, Gluud LL, Lund AB, Ellegaard AM.   +6 more
europepmc   +1 more source